ZDA
LAB icon

Zweig-DiMenna Associates’s Standard BioTools LAB Stock Holding History

Zweig-DiMenna Associates’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-140,535
Closed -$249K – 93
2024
Q2 		$249K Sell
140,535
-365,000
-72% -$892K 0.03% 75
2024
Q1 		$1.37M Buy
+505,535
New +$1.22M 0.12% 102

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Zweig-DiMenna Associates's LAB Position: Q3 2024 in Review

Zweig-DiMenna Associates sold out of Standard BioTools (LAB) in Q3 2024, closing a stake of 140,535 shares — an estimated $249K sold.

Zweig-DiMenna Associates first reported a position in LAB in Q1 2024 and held it in 2 quarters. The position peaked at $1.37M in Q1 2024. 141 funds tracked by Wall St. Rank hold LAB as of Q3 2024.

  • Zweig-DiMenna Associates reported no remaining Standard BioTools position as of Q3 2024 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 140,535 Standard BioTools shares in Q3 2024, an estimated $249K.
  • Zweig-DiMenna Associates first reported a position in Standard BioTools in Q1 2024 and held it in 2 quarters.
  • Zweig-DiMenna Associates's Standard BioTools position peaked at $1.37M in Q1 2024.
  • 141 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2024.

Based on Zweig-DiMenna Associates's 13F filing for Q3 2024, filed 23 Oct 2024.